ARGX
Price
$372.80
Change
+$4.20 (+1.14%)
Updated
Apr 26, 6:59 PM EST
12 days until earnings call
MDGL
Price
$193.33
Change
-$1.05 (-0.54%)
Updated
Apr 26, 6:59 PM EST
10 days until earnings call
Ad is loading...

Analysis and predictions ARGX vs MDGL

Header iconARGX vs MDGL Comparison
Open Charts ARGX vs MDGLBanner chart's image
argenx SE
Price$372.80
Change+$4.20 (+1.14%)
Volume$89.2K
CapitalizationN/A
Madrigal Pharmaceuticals
Price$193.33
Change-$1.05 (-0.54%)
Volume$181.13K
CapitalizationN/A
View a ticker or compare two or three
ARGX vs MDGL Comparison Chart

Loading...

ARGXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ARGX vs. MDGL commentary
Apr 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and MDGL is a Hold.

COMPARISON
Comparison
Apr 27, 2024
Stock price -- (ARGX: $372.80 vs. MDGL: $193.33)
Brand notoriety: ARGX and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 105% vs. MDGL: 81%
Market capitalization -- ARGX: $22.01B vs. MDGL: $4.05B
ARGX [@Biotechnology] is valued at $22.01B. MDGL’s [@Biotechnology] market capitalization is $4.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $556.22B to $0. The average market capitalization across the [@Biotechnology] industry is $2.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGX is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • ARGX’s TA Score: 4 bullish, 6 bearish.
  • MDGL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARGX is a better buy in the short-term than MDGL.

Price Growth

ARGX (@Biotechnology) experienced а +3.49% price change this week, while MDGL (@Biotechnology) price change was -8.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.69%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +1262.42%.

Reported Earning Dates

ARGX is expected to report earnings on Jul 25, 2024.

MDGL is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+1.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARGX with price predictions.
OPEN
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ARGX($22B) has a higher market cap than MDGL($4.05B). ARGX YTD gains are higher at: -3.110 vs. MDGL (-16.445).
ARGXMDGLARGX / MDGL
Capitalization22B4.05B543%
EBITDAN/AN/A-
Gain YTD-3.110-16.44519%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ARGX vs MDGL: Fundamental Ratings
ARGX
MDGL
OUTLOOK RATING
1..100
5864
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
2564
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
7563
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARGX's Valuation (54) in the Pharmaceuticals Other industry is in the same range as MDGL (66). This means that ARGX’s stock grew similarly to MDGL’s over the last 12 months.

ARGX's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is somewhat better than the same rating for MDGL (64). This means that ARGX’s stock grew somewhat faster than MDGL’s over the last 12 months.

ARGX's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as MDGL (99). This means that ARGX’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (63) in the Pharmaceuticals Other industry is in the same range as ARGX (75). This means that MDGL’s stock grew similarly to ARGX’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ARGX (100). This means that MDGL’s stock grew similarly to ARGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 1 day ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 1 day ago
72%
View a ticker or compare two or three
Ad is loading...
ARGXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LFEQ42.970.44
+1.04%
VanEck Lg/Flat Trend ETF
ARKG23.180.17
+0.74%
ARK Genomic Revolution ETF
INC26.320.07
+0.26%
VanEck® Dynamic High Income ETF
COMB20.60-0.01
-0.03%
GraniteShares Blmbrg CmdtyBrdStr NoK1ETF
USMF44.60-0.12
-0.28%
WisdomTree US Multifactor

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with BBIO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then BBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
-1.71%
BBIO - ARGX
51%
Loosely correlated
-2.80%
NRBO - ARGX
45%
Loosely correlated
-1.29%
MDGL - ARGX
43%
Loosely correlated
-5.02%
BLUE - ARGX
42%
Loosely correlated
-1.13%
AXON - ARGX
40%
Loosely correlated
+1.27%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with IBRX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then IBRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.54%
IBRX - MDGL
62%
Loosely correlated
+43.84%
KA - MDGL
62%
Loosely correlated
-4.66%
VXRT - MDGL
61%
Loosely correlated
+7.79%
VBIV - MDGL
57%
Loosely correlated
-4.24%
ALXO - MDGL
56%
Loosely correlated
-0.06%
More